Apollomics, Inc. (NASDAQ:APLMW) Short Interest Down 61.9% in January

Apollomics, Inc. (NASDAQ:APLMW) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 7,200 shares, a drop of 61.9% from the January 15th total of 18,900 shares. Based on an average daily volume of 86,900 shares, the short-interest ratio is presently 0.1 days.

Apollomics Price Performance

Apollomics stock opened at $0.01 on Thursday. The stock has a fifty day simple moving average of $0.01 and a two-hundred day simple moving average of $0.01. Apollomics has a 12 month low of $0.01 and a 12 month high of $0.04.

About Apollomics

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.